Intensity Therapeutics, Inc. INTS 深 沪
等待开盘 08-13 09:30:00 美东时间
0.2938
+0.024
+8.81%
华盛通- 最 高0.298
- 今 开0.2679
- 成交量 469.70万股
- 最 低 0.2585
- 昨 收 0.27
- 总市值 736.65万
- 52周最高 4.35
- 市盈率 静 --
- 换手率 18.73%
- 52周最低 0.1853
- 委 比 33.33%
- 总股本 2507.32万
- 历史最高 11.44
- 量 比 1.04
- 振 幅 14.63%
- 历史最低 0.1853
- 每 手 1
- 风险率 1.23%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 潜在涨幅921.1%！Intensity Therapeutics获Brookline Capital升级至"买入"，目标价上调至3美元
今日重点评级关注：Brookline Capital：上调Intensity Therapeutics评级至"买入"，目标价3美元；Chardan Capital：维持Taysha Gene Therapies"买入"评级，目标价从9美元升至10美元
今天 09:10
Intensity Therapeutics Amends Bylaws for Quorum Change
The latest update is out from Intensity Therapeutics, Inc. ( ($INTS) ). On Augu...
今天 05:15
Brookline Capital Upgrades Intensity Therapeutics to Buy, Announces $3 Price Target
Brookline Capital analyst Kumaraguru Raja upgrades Intensity Therapeutics (NASDAQ:INTS) from Hold to Buy and announces $3 price target.
今天 05:06
Intensity Therapeutics regains compliance with Nasdaq requirement
Intensity Therapeutics (NASDAQ:INTS) said on Tuesday that the biotechnology company has regained compliance with Nasdaq's minimum stockholders' equity requirement. On August 7, the company filed its q...
08-12 21:13
Intensity Therapeutics Regains Nasdaq Compliance
Intensity Therapeutics, Inc. (NASDAQ:INTS) ("Intensity" or "the Company"), a late-stage clinical biotechnology company focused on the discovery and development of novel intratumoral cancer therapies that are designed to
08-12 19:49
Intensity Therapeutics shares are trading higher after the company reported better-than-expected Q2 EPS results.
Intensity Therapeutics shares are trading higher after the company reported bet...
08-09 00:39
Intensity Therapeutics Q2 EPS $(0.13) Beats $(0.20) Estimate
Intensity Therapeutics (NASDAQ:INTS) reported quarterly losses of $(0.13) per share which beat the analyst consensus estimate of $(0.20) by 34.34 percent. This is a 63.89 percent increase over losses of $(0.36) per share
08-08 05:02
Intensity Therapeutics raises $6.6M via at-the-market offering
Intensity Therapeutics (NASDAQ:INTS) raised $6.6 million in gross proceeds last month through the sale of 19.86M shares via its at-the-market offering. The shares were sold at an average price of $0.3...
08-04 21:55
Intensity Therapeutics Raises $6.6M Through Stock Sales Of 19M Shares At $0.3323/Share to Fund Cancer Trials
Intensity Therapeutics, Inc. (NASDAQ:INTS) ("Intensity" or "the Company"), a late-stage clinical biotechnology company focused on the discovery and development of novel intratumoral cancer therapies that are
08-04 19:48
Oncology Innovation Just Hit a Turning Point -- Here's What to Watch
USA News Group News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 30, 2025 /PRNewswire/ -- USA News Group News Commentary – The oncology landscape is being pulle...
06-30 23:02
